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Introduction
Thyroid hormone (TH) homeostasis is essential for physiologic energy metabolism. Accordingly, alterations are linked to
a variety of diseases. With a prevalence of about 4% to 5% in
European and American populations, hypothyroidism (overt
and subclinical) is among the most common diagnoses in
endocrinology (Hollowell et al., 2002; Garmendia Madariaga
et al., 2014). TH homeostasis is tightly regulated by multiple
mechanisms, including those which control tissue uptake and
cellular bioactivation. Thyroxine (T4) is metabolized by intracellular iodothyronine deiodinases, which produce biologically
active triiodothyronine (T3) or inactive reverse triiodothyronine
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influence on the cellular accumulation of estrone-3-sulfate in the
steady state indicated that thyroid hormones were substrates of
OATP2B1. Additional evidence that thyroid hormones were
OATP2B1 substrates was provided by OATP2B1-dependent
stimulation of thyroid hormone receptor activation in cell-based
reporter assays. Bidirectional transport studies in intestinal
Caco-2 cells showed net absorptive flux of thyroid hormones,
which was attenuated by the presence of the OATP2B1 inhibitor,
atorvastatin. In intestinal Caco-2 and LS180 cells, but not in liver
Huh-7 or HepG2 cells, OATP2B1 expression was induced by
treatment with thyroid hormones. Reporter gene assays revealed
thyroid hormone receptor a–mediated transactivation of the
SLCO2B1 1b and the SLCO2B1 1e promoters. We conclude that
thyroid hormones are substrates and transcriptional regulators
of OATP2B1. These insights provide a potential mechanistic
basis for oral levothyroxine dose variability and drug interactions.

(rT3) (Köhrle, 2007). To signal transcription, T3 binds to
intracellular TH receptors (TRs) (Mondal et al., 2016). The
therapeutic management of hypothyroidism usually involves
oral substitution with levothyroxine [(L-thyroxine) T4]. However, oral absorption of L-thyroxine is highly variable and
known to be affected by various factors including gastric pH
or food-drug interactions (Ianiro et al., 2014). Furthermore, it
is known that efficient L-thyroxine absorption from the
intestinal lumen occurs in restricted segments of the gastrointestinal tract, namely, the duodenum and jejunum (Ianiro
et al., 2014).
Intestinal solute transfer is mainly mediated by passive
diffusion and active transport by membrane proteins. Several
well-known drug-drug interactions result in reduced
L-thyroxine bioavailability. For example, proton pump inhibitors alter the ionization status of L-thyroxine in the gut due to
increased gastric pH, while iron and calcium supplements
may form nonabsorbable chelates or complexes with THs
(Centanni et al., 2006). Interestingly, a population-based

ABBREVIATIONS: A, apical; ACN, acetonitrile; B, basal; DIO1, iodothyronine deiodinase 1; DMSO, dimethylsulfoxide; E1S, estrone-3-sulfate; FCS,
fetal calf serum; KHB, Krebs-Henseleit buffer; L-thyroxine, levothyroxine; MDCKII, Madin-Darby canine kidney II; OATP, organic anion transporting
polypeptide; Papp, apparent permeability; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; P-gp, P-glycoprotein; QC, quality
control; RPTEC, renal proximal tubular epithelial cell; rT3, reverse triiodothyronine; RXRa, retinoid X receptor alpha; T3, triiodothyronine; T4,
thyroxine; T4G, thyroxine 4-O-b D glucuronide; TH, thyroid hormone; TR, thyroid hormone receptor; TRa, thyroid hormone receptor alpha; TRb,
thyroid hormone receptor beta; UHPLC-MS/MS, ultra-high-performance liquid chromatography–tandem mass spectrometry.
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ABSTRACT
Levothyroxine replacement therapy forms the cornerstone of
hypothyroidism management. Variability in levothyroxine oral
absorption may contribute to the well-recognized large interpatient differences in required dose. Moreover, levothyroxine-drug
pharmacokinetic interactions are thought to be caused by
altered oral bioavailability. Interestingly, little is known regarding
the mechanisms contributing to levothyroxine absorption in the
gastrointestinal tract. Here, we aimed to determine whether the
intestinal drug uptake transporter organic anion transporting
polypeptide 2B1 (OATP2B1) may be involved in facilitating
intestinal absorption of thyroid hormones. We also explored
whether thyroid hormones regulate OATP2B1 gene expression.
In cultured Madin-Darby Canine Kidney II/OATP2B1 cells and in
OATP2B1-transfected Caco-2 cells, thyroid hormones were
found to inhibit OATP2B1-mediated uptake of estrone-3sulfate. Competitive counter-flow experiments evaluating the
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1B. For the OATP2B1-1E variant, liver-enriched expression
and regulation by HNF4a have recently been reported
(Knauer et al., 2013). In this study, we investigated the
functional and regulatory interplay of TH and the uptake
transporter OATP2B1. Using cells overexpressing OATP2B1,
we examined the impact of THs on cellular accumulation of
the known OATP2B1-substrate E1S. Cellular accumulation
studies were supplemented by counter-flow experiments and
an assessment of the influence of OATP2B1 on the transactivation of TH receptor beta (TRb). Finally, we used the
intestinal Caco-2 cell model to study transcellular TH transport as well as regulation of OATP2B1 expression.

Materials and Methods
Cell Culture. All cell lines were kept at 37°C in a humidified
atmosphere supplemented with 5% CO2. The cell lines Caco-2 (ATCC
HTB37), HepG2 (ATCC HB-8065), HeLa (ATCC CCL-2), and MadinDarby canine kidney II [(MDCKII) ATCC CRL-2936] were originally obtained from American Tissue Culture Collection (Molsheim
Cedex, France). Huh-7 cells (clone JCRB0403) were purchased from
the Japanese Collection of Research Bioresources (http://cellbank.
nibiohn.go.jp). Primary human renal proximal tubular epithelial
cells (RPTEC) were purchased from Ruwag Life science (Bettlach,
Switzerland). LS180 cells were commercially obtained from SigmaAldrich (Buchs, Switzerland). The OATP2B1 overexpressing cell line
MDCKII-OATP2B1 was generated and characterized as described
elsewhere (Grube et al., 2006). Dulbecco’s modified Eagle’s medium,
supplemented with 10% fetal calf serum (FCS), and 1% GlutaMAX
(Thermo Fisher Scientific, Zug, Switzerland) were used as culture
medium for the Caco-2, HeLa, HepG2, Huh-7, and MDCKII cells. In
the case of MDCKII-OATP2B1 the medium was supplemented with
0.25 mg/ml Hygromycin B for continuous selection. Dulbecco’s modified Eagle’s medium supplemented with 1% GlutaMAX, 10% FCS,
and 1% nonessential amino acids was the culture medium for the
LS180 cells. The RPTECs were kept in optimized Clonetics REGM
renal epithelial cell growth medium supplemented as recommended
by the manufacturer (Lonza, Basel, Switzerland).
In Silico Scan for Potential Thyroid Hormone Receptor
Binding Sites. The previously published sequences of the SLCO2B1
1b promoter and the SLCO2B1 1e promoter (Knauer et al., 2013) were
screened for potential TR binding sites using the open-access program
NUBIScan version 2.0 (www.nubiscan.unibas.ch). The underlying
algorithm is a joining of weighted distribution matrices of nucleotide
hexamer half-sites as published by Podvinec et al. (2002). The herein
used search matrix was generated based on previously described
specific DNA sequence binding pattern for TRs (Ayers et al., 2014).
Immunofluorescent Staining. Cells were seeded on cover slides
at a density of 75,000 cells/well in 12-well plates. After reaching 90%
confluence, cells were fixed with ice-cold methanol:aceton (1:2) for
15 minutes, permeabilized with 0.2% Tween 20/phosphate-buffered
saline (PBS), and then incubated with 5%-FCS-1% bovine serum
albumin/PBS before adding the anti-OATP2B1-antiserum (1:100)
(Grube et al., 2006) for incubation over night at 4°C. After several washes
with PBS, the secondary antibody, anti-rabbit Alexa Fluor 488 (Life
Technologies distributed by Thermo Fisher Scientific, Zug, Switzerland),
was added for 1 hour. Prior to mounting the cells with Roti-Mount
FluorCare containing 49,6-diamidino-2-phenylindole (DAPI) for nuclei
staining, the cells were washed with PBS. Staining was detected using the
Leica DMi8 Microscope (Leica Microsystems, Heerbrugg, Switzerland).
Quantitative Real-Time Polymerase Chain Reaction (PCR)
Analysis. Caco-2, LS180, Huh-7, and HepG2 cells were cultured at
confluence in six-well plates and then treated with 100 nM T4 or
100 nM T3. After 48 hours of treatment, total RNA was extracted using
TRIzol reagent (Thermo Fisher Scientific). The quality of the RNA was
determined using Agilent Bioanalyzer 2100 (Agilent, Santa Clara, CA)

Downloaded from molpharm.aspetjournals.org at ASPET Journals on July 4, 2022

retrospective study observed changes in thyroid-stimulating
hormone levels, a marker for TH activity, to be associated with
cotreatment with statins (Irving et al., 2015). Furthermore, an
acute impact of ciprofloxacin or rifampin on intestinal absorption of L-thyroxine was shown, where ciprofloxacin significantly reduced T4 area under the plasma concentration-time
curve by 39%, while rifampin significantly increased T4 area
under the plasma concentration-time curve by 25% (Goldberg
et al., 2013). These later findings suggest that L-thyroxinedrug interactions may also result from mechanisms involving
facilitated cellular entry or efflux (Riley et al., 2016).
With the discovery that MCT-8 (SLC16A2) genetic mutations cause Allan-Herndon-Dudley syndrome, a severe psychomotor retardation associated with TH dysregulation (Visser
et al., 2011), it has become widely accepted that transporters
are critically involved in the regulation of TH homeostasis and
function (Bernal et al., 2015). Additional transporters have
been reported to interact with THs, including members of the
organic anion transporting polypeptides (OATPs) (van der
Deure et al., 2010). Within this protein family, OATP1C1
appears to be highly active and specific for TH transport,
although it is only expressed at the blood-brain barrier and in
the testis (Pizzagalli et al., 2002; Sugiyama et al., 2003). In
addition, the hepatic transporters OATP1B1 and OATP1B3
have been reported to mediate cellular uptake of iodothyronine
sulfates (van der Deure et al., 2008), thereby contributing to
hepatic TH elimination. With regard to intestinal L-thyroxine
absorption, the aforementioned OATPs appear to be of
minor relevance due to their expression profile. In contrast,
OATP1A2 was reported to be expressed in intestine (Glaeser
et al., 2007) and to recognize THs as substrates (Fujiwara
et al., 2001). However, intestinal OATP1A2 expression could
not be subsequently confirmed; accordingly, the transporter is
mainly considered important for blood-brain transfer (Lee
et al., 2005; van der Deure et al., 2010).
A leading candidate for an intestinal TH transporter
is OATP2B1 (SLCO2B1). This sodium-independent uptake
transporter is expressed in enterocytes and assumed to
significantly influence oral drug absorption (Tamai et al.,
2000; Kullak-Ublick et al., 2001; Drozdzik et al., 2014). While
most studies supported localization of OATP2B1 at the apical
membrane of the enterocyte, its polarized cellular localization
is a matter of debate since basolateral sorting has recently
been proposed (Kobayashi et al., 2003; Keiser et al., 2017).
Despite OATP2B1 being known to mediate cellular uptake of
various exogenous compounds including statins (Koenen
et al., 2011), it is less certain whether this transporter is also
involved in intestinal absorption of THs since there are
conflicting data. Interestingly, both studies reporting data
on this used a similar experimental model involving Xenopus
laevis oocytes expressing OATP2B1 (Kullak-Ublick et al.,
2001; Leuthold et al., 2009). There are several transcription
start site variants of OATP2B1 (Pomari et al., 2009), which are
all regulated by their own distinct promoter (Fig. 8A, 1a to 1e).
Of these five variants the OATP2B1 isoform 1B (using exon 1b
as the transcription start site) encodes for the original fulllength protein and is the major form expressed in duodenum.
All other variants that are transcriptionally controlled by
different promoter regions encode for the same shortened
protein lacking 22 amino acids at the N-terminus. This short
variant exhibits transport of estrone-3-sulfate (E1S) and
rosuvastatin comparable to the full-length OATP2B1 isoform
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Cell-Based Reporter Gene Assays. To test the influence of
the uptake transporter on the intracellular function of T3 and T4,
MDCKII or MDCKII-OATP2B1 cells were transfected with a reporter
gene construct containing the firefly luciferase gene under the
control of the 59 untranslated region of the iodothyronine deiodinase
1 gene (DIO1-pGL3basic) and pRL-TK encoding for Renilla luciferase
as the transfection control. For cell-based reporter gene assays
testing the transactivation of the SLCO2B1 1e and SLCO2B1 1b
promoters, the respective reporter gene constructs in pGL3basic
(Knauer et al., 2013) were transfected into HeLa cells. In addition to
the reporter gene constructs, the cells were transfected with eukaryotic expression vectors (pEF6-V5/HIS; Invitrogen distributed by
Thermo Fisher Scientific) encoding for the nuclear receptor TRb,
TRa, and/or its heterodimerization partner retinoid X receptor alpha
(RXRa); in total, 25 ng pRL-TK, 250 ng of TRb-pEF6, TRa-pEF6,
and/or RXRa-pEF6 and/or pEF6 as control, and 250 ng of the
pGL3basic plasmid were transfected in each well. MDCKII or
MDCKII-OATP2B1 cells were seeded at a density of 40,000 cells/well
in a 24-well plate, and after 24 hours the cells were transfected using
1.5 ml/mg DNA of the jetPRIME transfection reagent (Polyplus
transfection). HeLa cells were seeded at a density of 50,000 cells/well
in 24-well plates, and were transfected using 2.5 ml/mg DNA of the
jetPRIME transfection reagent (Polyplus transfection). The next day,
the cells were treated for 24 hours with 10 mM T3 or 10 mM T4.
Subsequently, the cells were lysed in 100 ml passive lysis buffer, and
then the firefly and Renilla luciferase activities were assessed in 20 ml
of the lysate using the Dual-Luciferase Reporter Assay System
(Promega, Duebendorf, Switzerland) and the infinite 200 Pro (Tecan,
Maennedorf, Switzerland) according to the manufacturers’ instructions. Activity of firefly luciferase was normalized to that of Renilla.
Western Blot Analysis. For determination of protein content,
cells were lysed in 5 mM Tris-HCl (pH 7.4) supplemented with
protease inhibitors (diluted 1:100; Protease Inhibitors Cocktail;
Sigma-Aldrich). After three cycles of freezing in liquid nitrogen and
thawing in a 37°C water bath, the cell lysate of MDCKII cells was
centrifuged at 100,000g (30 minutes at 4°C) for crude membrane
enrichment. The resulting pellet was suspended in 5 mM Tris-HCl
supplemented with protease inhibitors. For cultured Caco-2 cells, we
applied the total cell lysate to immunoblotting. After adding 5x
Laemmli buffer, the samples were heated for 30 minutes to 65°C
prior to separation by 10% SDS-PAGE. The separated proteins were
electrotransferred to a nitrocellulose membrane using a TANK
blotting system (Bio-Rad, Cressier, Switzerland). Prior to incubation
with the respective antibodies, anti-OATP2B1 rabbit polyclonal
(Grube et al., 2006) or goat polyclonal anti-b-actin (sc-1616; Labforce,
Muttenz, Switzerland), the membranes were blocked with 5% FCS in
Tris-buffered saline containing 0.1% Tween 20 for at least an hour at
room temperature. After several washing steps with Tris-buffered
saline containing 0.1% Tween 20 the membranes were incubated with
the respective horseradish peroxidase-labeled secondary antibody
(dilution to 1:2000; Bio-Rad). Immobilized secondary antibody was
visualized and digitalized using Western ECL Substrate (Thermo
Fisher Scientific) and the ChemiDoc MP System (Bio-Rad), respectively. Analysis was performed using the Image Laboratory software
(version 4.1; Bio-Rad).
Transwell Transport of Thyroid Hormones. Transepithelial
solute flux studies were performed as previously published by
Hubatsch et al. (2007). Briefly, Caco-2 cells were seeded at a density
of 3  105 cells/well onto polycarbonate membranes with 0.4 mm pore
size inserted in 12-well plates (Chemie Brunschwig AG). Caco-2 cells
were cultivated for at least 14 days with medium change every second
day, and until reaching a transepithelial electrical resistance value of
at least 200 V/cm. Integrity of the monolayer was tested after
assessment of transport using 0.1 mg/ml lucifer yellow (SigmaAldrich). Transport experiments were performed using KHB. In
detail, after washing the cells with PBS, Caco-2 cells were preequilibrated for 20 minutes at 37°C with KHB. The apical compartment was filled with 0.5 ml of KHB, the basolateral compartment was
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and the concentration was measured by spectrophotometry (GE Nanovue Plus; GE Healthcare Life Sciences, Baie d’Urge, QC, Canada).
cDNA was synthesized using the Applied Biosystems Multiscribe
Reverse Transcriptase (distributed by LuBioScience, Lucern, Switzerland). Human tissue RNAs were purchased from AMS Biotechnology
(Bioggio-Lugano, Switzerland) or isolated from RPTEC, Caco-2, or Huh7 using pegGold RNA Pure (Axon Laboratory, Baden-Dättwil, Switzerland) following the manufacturer’s protocol. The Life Technologies
High-Capacity cDNA Reverse Transcription Kit (distributed by LuBioScience) was used for reverse transcription. The amount of mRNA was
quantified using the ViiA7 Real-Time PCR System and commercially
available TaqMan gene expression assays (LuBioScience) for TR beta
[(TRb), Hs00230861], TR alpha [(TRa), Hs00268470_m1], iodothyronine deiodinase 1 [(DIO1), Hs00174944_m1], and 18S ribosomal RNA
[(18S rRNA), 4319413E]. The amount of SLCO2B1 isoforms 1B and 1E
was analyzed using SYBR Green PCR Master Mix (LuBioScience)
and the following primers: SLCO2B1_1B_forward 59-GGCTGGAGCTCACTGCAC-39, SLCO2B1_1E_forward 59-TGGGATTGAAGCTTCAGGGAG-39, and SLCO2B1_1B/1E_reverse 59-CACTGTGGAAATGGAGCTC-39,
as previously reported by Knauer et al. (2013). In the cells, DIO1 and
ABCB1 were quantified using the primers DIO1_forward 59-TTCAGCACCAGTGGCCTATT-39, DIO1_reverse 59-ACGACTGAGCTAGGGGGTCT-39,
P-glycoprotein (P-gp)_forward 59-GTCCCAGGAG-CCCATCCT-39, and
P-gp_reverse 59-CCCGGGTGTTGTCTCCAT-39. Data were analyzed by
the DDCT method, where the CT values of the gene of interest were
normalized to that of 18S rRNA detected in the same sample (DCT). The
DCT values of each sample were referred to the mean DCT value of the
indicated control (DDCT).
Transport Studies Using MDCKII-OATP2B1 Cells. For inhibition studies and competitive counter-flow experiments, MDCKII
or MDCKII-OATP2B1 cells were seeded at a density of 50,000
cells/well in 24-well plates. One day after seeding, cells were
stimulated with 2.5 mM sodium-butyrate for 24 hours. For inhibition
studies, cells were washed with prewarmed PBS prior to the 5-minute
incubation with E1S diluted in incubation buffer (142 mM NaCl, 5 mM
KCl, 1 mM KH2PO4, 1.5 mM CaCl2, 1.2 mM MgSO4, 5 mM glucose,
and 12.5 mM HEPES). E1S was used at a concentration of 0.1 mM
containing 100,000 dpm/well [ 3 H]-E 1 S (Hartmann Analytic,
Braunschweig, Germany), supplemented with the respective
concentration of the tested inhibitor, namely, T4, T3, rT3, and
thyroxine 4-O-b-D-glucuronide (T4G) (all obtained from SigmaAldrich). Atorvastatin [1 or 10 mM] was used as the control. After
washing the cells three times with ice-cold PBS, cells were lysed in
200 ml 10% SDS-5 mM EDTA. Cellular accumulation of the radiolabeled substrate was determined after diluting the cell lysate in 2 ml of
scintillation cocktail (Rotiszint eco plus; Carl Roth AG, Arlesheim,
Switzerland) and measured using a liquid scintillation b-counter (Tricarb 2900 TR; TOPLAB, Rickenbach, Switzerland). Competitive
counter-flow experiments were performed as described by Harper
and Wright (2013). One day after seeding, the cells were washed once
with prewarmed PBS and exposed to Krebs-Henseleit buffer [(KHB);
118 mM NaCl, 25 mM NaHCO3, 1.2 mM KH2PO4; 2.5 mM CaCl2,
1.2 mM MgSO4, 11 mM glucose, 4.7 mM KCl, pH 5.5] containing [3H]E1S (6.06 nM/well with 100,000 dpm/well) for 30 minutes to equilibrate. After reaching steady-state conditions, the supernatant was
removed and replaced by KHB containing [3H]-E1S supplemented
with the test compounds, namely, E1S (50 mM), atorvastatin (30 mM),
camptothecin (1 mM), T4 (25 mM), T3 (10 mM), rT3 (1 mM), or T4G
(400 mM). After 1-minute incubation the cells were washed with icecold PBS and the amount of radiolabel in the lysed cells was
determined as described previously.
Transport Studies Using Transiently Transfected Caco-2
Cells. Caco-2 cells were seeded at a density of 75,000 cells/well in
24-well plates. One day after seeding the cells were transfected with
500 ng/well pEF6-control or OATP2B1-pEF6 using 2 ml/mg DNA
jetPRIME transfection reagent (Polyplus transfection; Chemie
Brunschwig AG, Basel, Switzerland), and the next day transport
experiments were conducted as previously described in detail.

OATP2B1, an Intestinal Thyroid Hormone Transporter
TABLE 1
Optimized tandem mass spectrometry parameters in electrospray
ionization positive mode for analytes and the corresponding internal
standards
Cone Voltage
Analyte I.S.

MRM Transition

T3
I.S.
T4
I.S.

651.6
658.0
777.3
783.4

13

C 6 T3

13

C 6 T4

→
→
→
→

197.1
612.0
633.8
737.7

Collision
Energy

V

eV

55
50
60
55

80
32
42
32

I.S., internal standard; MRM, multiple reaction monitoring.

uptake 2 ratio 5

Papp ðA to BÞ
Papp ðB to AÞ

Triiodothyronine and Thyroxine Quantification by UHPLCMS/MS. For the quantification of T3 and T4 in the range of 30–
3000 ng/ml, specific UHPLC-MS/MS methods were developed. For both
T3 and T4, seven calibration standards (calibrators) and three levels of
quality controls (QCs) in KHB at low (QC 90 ng/ml), medium (QC
1500 ng/ml), and high (QC 2400 ng/ml) concentrations were prepared by
serial dilution of the respective working solution (100 mg/ml in methanol
for both T3 and T4). The first concentration (30 ng/ml) of the calibrators
was defined as the lower limit of quantification, and the highest
concentration (3000 ng/ml) was defined as the upper limit of quantification.
Calibrators and QCs were stored in aliquots in polypropylene tubes
below 265°C until analysis. 13C6-T3 and 13C6-T4 (dissolved to 1000 ng/ml in
methanol; Sigma-Aldrich) were used as internal standards for T3 and T4,
respectively. To 20 ml of the KHB samples from the Transwell studies,
100 ml of each internal standard, 200 ml bovine serum albumin solution
(60 g/l), and 700 ml of ice-cold acetonitrile (ACN) were added. The mixture
was briefly vortexed, mixed for 10 minutes at 1400 rpm and room
temperature, and then centrifuged for 20 minutes at 13,200 rpm and
10°C. The supernatant was transferred into a 96-deep-well plate, dried
under heated nitrogen gas flow (30–50°C; Evaporex EVX-96; Apricot
Designs, Monovia, CA), and reconstituted with 200 ml of injection solvent
(35% eluent A and 65% eluent B; eluent A: 0.1% formic acid in water;
eluent B: 0.1% formic acid in ACN) under shaking (1500 rpm) for
45 minutes at room temperature. Subsequently, each sample was transferred into a 300 ml glass insert of a high-performance liquid chromatography vial before injection into the UHPLC-MS/MS system in full-loop
mode (5 ml). Quantification was performed using an UPLC HSS T3 column
on an Acquity UPLC system consisting of a binary pump, an autosampler
set at 10°C, and a column heater set at 45°C, which was coupled to an
Acquity TQD tandem mass spectrometer (all obtained from Waters Corp.,
Milford, MA). The mobile phase consisted of eluents A and B. Chromatographic separation was performed at a flow rate of 0.5 ml/min with the
following gradient: 0 to 1 minute, B 5%; 1–5 minutes, B 5%–100%; 5 to
6 minutes, B 100%; 6–6.01 minutes, B 100%–5%; 6.01–7 minutes, B 5%.

Fig. 1. Validation of OATP2B1 expression and function in stably transfected MDCKII cells. Immunofluorescent staining of MDCKII-OATP2B1 and
MDCKII cells revealed localization of the transporter in the basolateral membrane of polarized MDCKII cells overexpressing the transporter. No signal
was observed in MDCKII cells (A). Immunoblot analysis verified high expression when comparing MDCKII and MDCKII-OATP2B1 cells, as shown in the
representative blot (B). Uptake of [3H]-E1S was significantly enhanced in the presence of the transporter, while it was reduced by co-incubation with
atorvastatin (C).
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filled with 1.5 ml of KHB, and 10 mM T3 or 10 mM T4 was applied to the
donor compartment. Inhibition of OATP2B1 was achieved by application of 10 mM atorvastatin (USP, Basel, Switzerland) on the apical
site. Accumulation in the acceptor compartment and remaining
amount in the donor compartment was quantified in 200 ml aliquots
taken at 30 minutes and replaced with KHB buffer. At 60 minutes a
second aliquot was taken. Both apical and basolateral KHB samples
were stored in glass vials (to avoid long-term nonspecific adsorption)
below 265°C prior to quantification by ultra-high-performance liquid
chromatography–tandem mass spectrometry (UHPLC-MS/MS) as
described subsequently. The apparent permeability (Papp) coefficient
was calculated as previously described (Hubatsch et al., 2007).
The determined unidirectional apparent permeability coefficients in
the apical (A)-to-basal (B) or B-to-A direction were used to calculate the
uptake ratio. In accordance with the commonly used efflux ratio, the
uptake ratio was calculated as follows:
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In addition to the aforementioned injection solvent and eluents, the weak
and strong wash solvents were water-ACN (50:50, v/v) containing 0.2%
trifluoroacetic acid, and ACN-isopropanol-acetone (40:40:30, v/v/v) containing 0.2% trifluoroacetic acid, respectively. The seal wash solvent
consisted of a water-ACN mixture (90:10, v/v). Multiple reaction monitoring detection was performed with electrospray ionization in positive ion
mode. Nitrogen was used both as desolvation and nebulization gas. Argon
was used as collision gas. The tandem mass spectrometry parameters were
generated using IntelliStart software (Waters Corp.) followed by manual
optimization. The optimized parameters are summarized in Table 1.
Statistical Analysis. Data are presented as mean 6 S.D. Data
analysis was performed using GraphPad Prism software version 6.04
(GraphPad Software Inc., San Diego, CA) and Microsoft Excel (Microsoft, Redmond, WA). Values of P # 0.05 were considered as statistically significant.

Results
Influence of Thyroid Hormones on OATP2B1 Transport Activity. In a first approach, we tested the influence of

T4 and its metabolic products, namely T3, rT3, and T4G (Fig.
2A) on OATP2B1-mediated uptake of the known substrate
E1S using OATP2B1 expressing MDCKII cells. Expression of
OATP2B1 (isoform 1B) in the cell model was verified by
immunofluorescence microscopy (Fig. 1A) and western blot
analysis (Fig. 1B) showing localization of OATP2B1 at the
plasma membrane of overexpressing MDCKII-OATP2B1
cells. As shown in Fig. 2, B–E, all of the tested compounds
significantly inhibited OATP2B1 transport function, thereby
providing the first evidence of an interaction of THs with this
membrane transporter. OATP2B1 function was potently
inhibited by T4 (IC50 2.43 mM, CI 2.91–3.08) and T3 (IC50
0.51 mM CI 0.39–0.64), while rT3 (IC50 14.88 mM CI 12.16–
18.21) and T4G (IC50 44.55 mM CI 36.07–55.03) exhibited
lower inhibitory potency. Inhibition of OATP2B1 by the
known OATP2B1 substrate, atorvastatin, served as a positive
control of the experimental system (Fig. 1C). The influence of
TH derivatives was also tested in Caco-2 cells transiently
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Fig. 2. Inhibition of OATP2B1-mediated uptake by TH derivatives. Uptake of [3H]-E1S in MDCKII-OATP2B1 was determined in the presence of
different THs derived from T4 (A). Cellular accumulation of E1S was determined after incubation with increasing concentrations of T4, (B), T3 (C), rT3 (D),
or T4G (E). The logarithmic inhibitor response curves were fitted to determine the IC50 values and the respective confidence intervals (CI). The data
presented are of n = 3 independent replicates each in triplicate.
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transfected with OATP2B1-pEF6 for overexpression of the
transport protein. Using this cell model, we also observed
inhibition of OATP2B1-mediated cellular accumulation of E1S
for T4 (IC50 4.81 mM, CI 3.65–6.34), T3 (IC50 0.97 mM CI 0.61–
1.53), rT3 (IC50 16.10 mM CI 11.44–22.65), and T4G (IC50
57.21 mM CI 38.11–85.89). Notably, the transport rate of E1S
in OATP2B1-transfected Caco-2 cells was lower than that
observed for stably transfected MDCKII-OATP2B1 cells
(mean transport rate 6 S.D.; fmol mg protein21/min21; Caco2-OATP2B1 vs. MDCKII-OATP2B1; 0.268 6 0.055 vs. 1.226 6
0.086; n 5 3 independent replicates, each in biologic triplicate;
P , 0.05; ordinary one-way analysis of variance with Turkey’s
multiple comparisons test).
Competitive Counter-Flow Transport Studies with
Thyroid Hormones in OATP2B1-Expressing Cells. Subsequently, competitive counter-flow experiments were conducted to determine whether the observed inhibition is due to
transport of the tested TH derivative. Counter-flow was

assessed in MDCKII-OATP2B1 cells at equilibrium, which
was reached after 30 minutes of incubation with E1S (compare
Fig. 3A). An examination of the remaining amount of radiolabeled [3H]-E1S in cells exposed to T4 (25 mM), T3 (10 mM),
and rT3 (1 mM) revealed significantly lower levels of the
radiolabel compared with cells exposed to dimethylsulfoxide
(DMSO) vehicle control (mean percentage of DMSO control 6
S.D.; T4: 39.41% 6 9.93%, T3: 40.34% 6 10.37%; rT3: 57.20% 6
15.37%; one-way analysis of variance with Dunnett’s multiple
comparisons test; P , 0.05), suggesting that these compounds
are OATP2B1 substrates. In this assay, the known OATP2B1
substrates atorvastatin (30 mM; 28.33% 6 6.17%) and E1S
(50 mM; 42.31% 6 8.26%) expectedly reduced intracellular E1S
after addition in the steady state. Lastly, T4G (400 mM; 80.70% 6
33.70%) and camptothecin (97.71% 6 14.07%) did not affect
cellular E1S equilibrium (Fig. 3B), indicating that these compounds were not substrates of OATP2B1.
Influence of OATP2B1 Transport Function on Intracellular Thyroid Hormone Effects. To provide additional evidence for OATP2B1 transport of THs, we tested the
impact of OATP2B1 expression on intracellular TH signaling.
MDCKII or MDCKII-OATP2B1 cells were used for cell-based
reporter gene assays that examined transactivation of the
human DIO1 promoter (see the illustration below the graphs
in Fig. 4). With overexpression of the OATP2B1 transporter,
transactivation of the DIO1 promoter was significantly enhanced by both T3 and T4 with cotransfection of TRb with or
without RXRa (Fig. 4, A and B). Thyroid hormones did not
activate the DIO1 promoter in both cell lines transfected with
just RXRa (Fig. 4C); indicating the signal enhancement was
TRb dependent. It is notable that the transfection efficacy in
MDCKII was much lower than that of HepG2 or HeLa cells in
cell-based reporter gene assays conducted in our laboratory.
This, in part, explains the lower transactivation of the DIO1
promoter by about 3-fold, since we usually see a transactivation of about 5- to 6-fold compared with vector control in
experiments with cells better accessible by transfection.
Expression of OATP2B1 and TRb in Human Tissues
and Cellular Models. Different tissues and commonly used
cellular models of those organs were analyzed by real-time
PCR to determine endogenous expression of the transporter
OATP2B1 isoform 1B, OATP2B1 isoform 1E, TRb, TRa, and
DIO1. The DIO1 was only observed in liver kidney, and in
Caco-2, HepG2, Huh-7, and RPTECs but not in LS180 cells
(mean expression 6 S.D., relative to liver, Caco-2 vs. LS180 vs.
Huh-7 vs. HepG2 vs. RPTEC, DIOI: 0.779 6 0.313 vs. not
detected vs. 0.038 6 0.003 vs. 0.162 6 0.027 vs. 0.006 6 0.006,
data not shown). As shown in Fig. 5, A and B, the mRNA of
TRa or TRb was observed in all tissues studied. Examination
of the mRNA expression of the OATP2B1 isoforms verified the
previous observation of isoform 1B as enriched in the intestine, while isoform 1E (Fig. 5E) was predominantly
expressed in liver (Fig. 5F) (Knauer et al., 2013). For all genes
examined in different cell models, the highest expression
levels were observed in intestinal Caco-2 cells compared with
LS180, Huh-7, HepG2, and RPTEC (mean expression 6 S.D.,
relative to liver, Caco-2 vs. LS180 vs. Huh-7 vs. HepG2 vs.
RPTEC, TRa: 36.266 6 7.289 vs. 28.116 6 6.395 vs. 12.942 6
3.582 vs. 2.815 6 0.374 vs. 7.531 6 1.686; TRb: 4.521 6 1.224
vs. 4.321 6 0.372 vs. 4.614 6 0.315 vs. 1.022 6 0.162 vs. 1.384 6
0.157, OATP2B1-1B: 149.599 6 66.648 vs. not detected vs.
14.071 6 4.627 vs. 5.358 6 0.956 vs. 0.145 6 0.074 and
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Fig. 3. Competitive counter-flow assays in MDCKII-OATP2B1 cells.
Assessment of time-dependent accumulation of [3H]-E1S comparing
MDCKII and MDCKII-OATP2B1 cells (A). Counter-flow experiments
were conducted after reaching the steady state of E1S at 30 minutes of
incubation. The cellular amount of the radiotracer was determined after
1 minute of incubation with 50 mM E1S, 30 mM atorvastatin, 1 mM
camptothecin, 25 mM T4, 10 mM T3, 1 mM rT3, or 400 mM T4G (B). The
detected amount of radiotracer was normalized to that in cells treated with
the solvent control. Data are presented as mean 6 S.D. (n = 3 independent
replicates each in triplicate). For the statistical analysis, one-way analysis
of variance with Dunnett’s multiple comparisons test was used (*P # 0.05).
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Fig. 4. Influence of OATP2B1 expression on transactivation of the DIO1
promoter. Transactivation of the DIO1 promoter was determined by cellbased dual luciferase assays comparing MDCKII with MDCKII-OATP2B1
cells (see the illustration below the graphs). Luciferase activity was
assessed after treatment with T3 or T4. MDCKII or MDCKII-OATP2B1
cells were transfected with DIO1-pGL3basic and eukaryotic expression
vectors encoding for TRb (A), RXRa (B) or both (C). Data are presented as

mean 6 S.D. (n = 3 independent replicates each in triplicate). For the
statistical analysis, two-way analysis of variance with Sidak’s multiple
comparisons test was used (*P # 0.05).
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OATP2B1-1E: 9.278 6 2.381 vs. 3.553 6 0.334 vs. 0.297 6 0.073
vs. 0.222 6 0.083 vs. 0.002 6 0.001; Fig. 5, C, D, G, and H),
thereby supporting further use of Caco-2 cells for in vitro
studies on the interactions of OATP2B1 and THs.
Quantification of Transcellular Transport of Thyroxine and Triiodothyronine in Caco-2 Cells. Transcellular
flux of T4 or T3 was assessed in differentiated Caco-2 cells
cultured in Transwells. The amount of T4 and T3 in the apical
or basal compartment was quantified by UHPLC-MS/MS.
Solute flux studies in the A-to-B direction revealed that T4
exhibits intermediate permeability, while T3 shows low
permeability since the Papp value was below 3.3  1026 cm/s
[mean Papp (A-B) 6 S.D. (cm/s), T4: 3.70  1026 6 0.17  1026;
T3: 2.75  1026 6 7.08  1029]. Lower permeability was
observed when examining transcellular transfer of THs in the
B-to-A direction [mean Papp (B-A) 6 S.D. (cm/s), T4: 2.08  1026 6
1.55  1029; T3: 0.893  1026 6 2.51  1029]. Similar results
were obtained with T4 and T3 permeability after 60 minutes of
incubation using the same system in the A-to-B direction [mean
Papp (A-B) 6 S.D. (cm/s); T4: 2.75  1026 6 0.57  1026; T3: 3.36 
1026 6 0.77  1026, data not shown] or B-to-A direction [mean
Papp (A-B) 6 S.D. (cm/s); T4: 2.34  1026 6 0.32  1026; T3: 1.74 
1026 6 0.36  1026]. However, calculating the uptake ratio—
which was conducted in a similar manner as the commonly used
efflux ratio, but by dividing Papp (A-B) by Papp (B-A)—revealed
factors of 1.779 6 0.130 and 3.203 6 0.909 for T4 and T3,
respectively; highlighting that there is a component in cellular
transfer that enhances A-to-B flux, despite that low permeability
observed. Addition of atorvastatin (10 mM) as a known inhibitor of OATP2B1 in the bidirectional permeability assessment
significantly changed the uptake ratios (Papp (A-B)/Papp (B-A)) for
T4 and T3 (Fig. 6). These results indicate the presence of
atorvastatin-sensitive, TH transporters in Caco-2 cells.
Transcriptional Regulation of OATP2B1 by Thyroid
Hormones. Furthermore, we examined whether T4 (100 nM)
or T3 (100 nM) treatment influences the expression of
OATP2B1 variants in Caco-2 or Huh-7 cells. Both OATP2B1
1B and 1E variants are expressed in Caco-2 and Huh-7 cells
(Knauer et al., 2013). We found that T3 and T4 treatments
increased the mRNA expression of the intestinal OATP2B1 1B
variant by 10-fold (mean % of DMSO control 6 S.E.M., 1008% 6
240% of control, P , 0.05), and 4.8-fold (480% 6 140% of control,
P , 0.05), respectively, in Caco-2 cells (Fig. 7A). However, the
THs did not appreciably increase the OATP2B1 1B mRNA
expression in Huh-7 cells (Fig. 7D). The liver-enriched
OATP2B1 1E variant mRNA expression was also induced 5.5fold (549% 6 118% of control, P , 0.05) by T3 and 2.7-fold (265%
6 69% of control, P , 0.05) by T4 in Caco-2 cells (Fig. 7B), but
again not in Huh-7 cells (Fig. 7E). For controls, we examined the
expression of DIO1 and ABCB1 (P-gp); two well-recognized TR
target genes. As expected, both T3 and T4 treatments induced
the expression of DIO1 in both Caco-2 (Fig. 7C) and Huh-7 cells
(Fig. 7F). Induction was also observed for the expression
of ABCB1 in Caco-2 (mean % of DMSO control 6 S.D., T3:
9100% 6 8366%; T4: 2054% 6 507.8%; n 5 5, Kuskal-Wallis
test, P , 0.05) and in Huh-7 cells (T3: 148.2% 6 52.6%; T4:
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161.1% 6 63.87%; n 5 5, Kuskal-Wallis test, P , 0.05) (data not
shown). Similar results were observed when testing the influence of THs on OATP2B1 protein expression in differentiated
Caco-2 cells cultivated for 14 days prior to TH exposure. As
shown in Fig. 7, G and H, expression of OATP2B1 was
significantly increased by 2.6-fold in the presence of T3 and by
2.9-fold in the presence of T4. We additionally examined
TH-mediated regulation of OATP2B1 expression in other
intestinal and liver cell lines. With intestinal LS180 cells, there
was significant increment in the OATP2B1 isoform 1E mRNA
expression after exposure to T3 (mean expression % of DMSO
control 6 S.D.; DMSO vs. T3 vs. T4; 117.92 6 12.99 vs. 294.07 6
41.46 vs. 244.36 6 156.71; n 5 3 independent replicates each in
triplicate; P , 0.05; Kruskal-Wallis test with Dunn’s multiple
comparisons test). In LS180 cells, the amount of ABCB1 mRNA
was also significantly increased by T3 treatment (DMSO vs. T3
vs. T4; 121.93 6 16.95 vs. 1286.14 6 256.45 vs. 738.32 6 400.22;
P , 0.05). However, for both genes we did not observe changes in
expression after exposure of LS180 cells to T4. It is notable that
the mRNA expressions of the OATP2B1 1B variant and that of
DIO1 were not detected in LS180 cells. In HepG2 cells we tested
the influence of T3 on DIO1, ABCB1, and the OATP2B1 variants,
and observed no significant change in mRNA expression of any
gene (mean expression % of DMSO control 6 S.D.; DMSO vs. T3
DIO1: 105.01 6 2.81 vs. 155.71 6 19.93; ABCB1: 105.99 6 2.48
vs. 89.96 6 15.25; OATP2B1 1E: 103.81 6 1.64 vs. 144.9 6 10.11;
OATP2B1 1B 104.81 6 2.22 vs. 139.92 6 5.60; n 5 3 independent
replicates each in triplicate; P . 0.05 n 5 3 independent

replicates each in triplicate; Mann-Whitney test). Taken together, these results demonstrate that THs are positive regulators of OATP2B1 gene expression in a cell type–dependent
manner.
OATP2B1 Promoter Analysis and Cell-Based Reporter Gene Assays. Transcriptional regulation by THs is
mediated by TRs. These nuclear receptors bind to DNA
response elements in the promoter region of their target
genes. We performed an in silico analysis to search for the
TR DNA-binding motifs DR4, ER6, and DR1 in the SLCO2B1
1b or SLCO2B1 1e promoters (Knauer et al., 2013). As
summarized in Table 2 and shown in Fig. 8A, multiple
potential response elements for TRs were identified in the
sequences analyzed. In detail, the ER6 motif (AGTCCTcagtccAGGAAA) in positions 2899 to 2882 exhibited the highest
rank in the analysis of the SLCO2B1 1b promoter sequence,
while the previously reported DR1 motif (AGGGCAaAGTCCA
in positions 217 to 24), had the highest score in the SLCO2B1
1e promoter. Considering the differential tissue/cell expression of TRa and cell-type specific induction of OATP2B1 by
THs, we examined whether the SLCO2B1 1b and SLCO2B1
1 e promoters were activated in the presence of TRa and its
activating ligand T3 in cell-based luciferase assays. The
TR-sensitive DIO1 promoter served as the control in these
experiments. We observed significantly enhanced luciferase
activity after treatment with T3 in HeLa cells transfected
with the SLCO2B1 1b promoter (mean luciferase activity
fold of pGL3b control 6 S.D.; DMSO vs. T3; 1.364 6 0.141 vs.
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Fig. 5. Gene expression analysis in tissues and commonly used cellular models. Expression of TRa and TRb was quantified by real-time PCR in different
human tissues (A and B) and corresponding cellular models (C and D) using specific TaqMan gene expression assays. In addition, mRNA amount of two
isoforms of the OATP2B1 was assessed. Both isoform 1B and isoform 1E (SLCO2B1 1B and 1E) were quantified with SYBRgreen assays (E–H). Relative
expression of each gene was calculated according to the DDCt method. Data are presented as mean 6 S.D., n = 3 independent replicates each in triplicate.
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2.268 6 0.444; P , 0.05 student’s t test, Fig. 8B). Similarly, T3
treatment enhanced the SLCO2B1 1e promoter luciferase
activity (1.197 6 0.142 vs. 2.260 6 0.485; P , 0.05 student’s t
test, Fig. 8C). These results demonstrate that both SLCO2B1
1b and SLCO2B1 1e promoters are transactivated by TRa.

Discussion
We report interaction of THs with the function and
expression of OATP2B1. This ubiquitously expressed transporter, with suspected function in the intestinal absorption of
drugs, was inhibited by all TH derivatives tested in
OATP2B1-expressing cells. Furthermore, counter-flow experiments assessing the influence of TH derivatives on the
cellular equilibrium of E1S at steady state suggested that
T3, T4 and rT3 are not only inhibitors but also substrates of
OATP2B1. This notion was further supported by findings
showing that the presence of OATP2B1 significantly enhanced intracellular TH signaling as observed in cell-based
reporter gene assays comparing MDCKII and MDCKIIOATP2B1 cells. The presence of an active transport component in the transcellular transport of T3 and T4 was supported
by results of transcellular flux experiments in the intestinal
cell line Caco-2. Indeed, we observed enhanced permeability
in the A-to-B direction for both T4 and T3, resulting in uptake
ratios (Papp (A-B)/Papp (B-A)) of about 1.8 and about 3.2 for T4

and T3, respectively. Atorvastatin, which is a known substrate and competitive inhibitor of OATP2B1 (Grube et al.,
2006), significantly reduced this ratio for T3 and T4. The
observed reduction in the TH uptake ratio by atorvastatin
could certainly be interpreted in terms of reduced uptake
mediated by apically localized OATP2B1, but it should also be
noted that multiple transporters are expressed in enterocytes
and Caco-2 cells, of relevance being the efflux transporter
ABCB1 (P-gp), which has previously been reported to also
transport T3 (Mitchell et al., 2005). Moreover, atorvastatin is
not a specific OATP2B1 inhibitor, and thus also interacts with
several efflux transporters including the aforementioned
ABCB1 (Chen et al., 2005). Despite that, we observed reduction in the net absorption of THs in the presence of
atorvastatin in Caco-2 cells, even if it is likely that there
has been reduced apical TH efflux by ABCB1 in the presence
of atorvastatin.
As previously mentioned, localization of OATP2B1 in
enterocytes is a matter of an ongoing debate, which was
sparked by recent experiments by Kaiser et al. (2017), indicating that OATP2B1 is localized in the basolateral membrane of enterocytes. This localization would be expected to
result in an increase in the uptake ratio of OATP2B1
substrates in the presence of an inhibitor specific to this
transporter, which has not been observed in the herein
reported experiments. Even if we are not able to dissect the
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Fig. 6. Transcellular flux of THs and localization of OATP2B1 in cultured Caco-2 cells. Caco-2 cells cultivated for 14 days in a Transwell system were
used to assess apical-to-basolateral (A-B) or basolateral-to-apical (B-A) flux of T4, or T3 in presence of solvent control (DMSO), or atorvastatin (10 mM).
The unidirectional Papp coefficients for T4 (B) and T3 (D) were used to calculate the uptake ratios [Papp (A-B)/Papp (B-A)] for T4 (A) and T3 (C). Data are
presented as mean 6 S.D. (n = 3 independent replicates). For statistical analysis, Sidak’s multiple comparisons test was used (*P # 0.05).
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Fig. 7. Influence of THs on expression of OATP2B1. Expression of SLCO2B1 isoform 1B (A) SLCO2B1 isoform 1E (B) and deiodinase type 1 (C) mRNA
was quantified by real-time PCR after 48 hours of treatment of differentiated Caco-2 cells with T3 (100 nM) or L-thyroxine (T4, 100 nM). Amount of
SLCO2B1 isoform 1B (D), SLCO2B1 isoform 1E (E), and deiodinase type 1 (F) mRNA was quantified by real-time PCR in Huh-7 cells treated with T3
(100 nM) or T4 (100 nM). Expression data were calculated by the DD-Ct method, where expression was related to that of a housekeeping gene and then
normalized to the solvent control. Data are presented as mean 6 S.E.M. of n = 5 experiments. Gene expression was analyzed with a Kruskal-Wallis test
with Dunn’s multiple comparisons test. OATP2B1 protein expression was assessed by western blot analysis [representative result, (G)]. Actin served as
the loading control (H). Data obtained by densitometry of n = 3 experiments are presented as mean 6 S.D., and comparisons were analyzed by one-way
analysis of variance with Dunnett’s multiple comparisons test (E) (*P , 0.05).

contribution of each Caco-2 transporter to TH fluxes since
atorvastatin is a potent inhibitor of OATP2B1, but not specific
for this transporter, our observation, which showed a reduction in the ratio, would be in agreement with findings by
others showing expression of OATP2B1 in the apical membrane of enterocytes and Caco-2 cells (Tamai et al., 2001;
Kobayashi et al., 2003).
Our data demonstrated inhibition of OATP2B1 function by
T3 and T4 with in vitro IC50 values in the micromolar range.

Whether this inhibition is of clinical relevance with respect to
TH being a perpetrator of pharmacokinetic drug interactions,
especially in other tissues than intestine, is uncertain.
However, normal T4 plasma concentrations range from 0.59
to 1.54 mM. Furthermore, T4 is significantly bound to serum
proteins resulting in free T4 concentrations of 0.09–0.24 nM.
Considering these low physiologic free plasma concentrations,
it seems unlikely that T4 would alter the tissue distribution/
elimination of drugs through inhibition of OATP2B1. Similar
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TABLE 2
Summary of potential TR response elements in the SLCO2B1 1b and SLCO2B1 1e promoter region
Analysis was performed using the publically available NUBIscan software. Response element marked with † exhibited
the highest score in the in silico analysis for this particular motif. Response element highlighted in bold had the highest
score in the analysis of the respective promoter fragment. Response element marked with * was previously reported to be
the most likely HNF4a binding site, resulting in constitutive activity of the promoter in cells, where this transcription
factor is present (Knauer et al., 2013).
Motif

Position

GGGTCTgatcAGGTCA
AGGACAgagaAGCCAA
TATCCTgggtggAGGGAA
AGTCCTcagtccAGGAAA
AGGCTGgaaaAGGACA

21756 to 21741
21078 to 21063
21362 to 21345
2899 to 2882
2405 to 2390

AGCACAtctgAGGCAA
AGAGCAaGGGCCA
TGACCTatttcaGGGTGA
AGGTGGgagaAGGTCA
AGGTCTgAGGCCT
AGGACAgATCTCA
AGCCCAcAGGAAA
AGGGAAgcacTGGCC
TGGGCAggggAGGGAA
AGGGCAaAGTCCA

22170 to 22186
22136 to 22149
21241 to 21223
21222 to 21206
2996 to 983
2954 to 2941
2167 to 2155
255 to 240
246 to 230
217 to 24

considerations could be taken for T3, whose physiologic
plasma total concentrations range from 0.01 to 0.03 mM.
At the clinical level, little is known regarding the role of
OATP2B1 in the intestinal absorption of L-thyroxine. A
clinical study was conducted by Lilja et al. (2005), motivated
by a case in which a patient experienced significant changes in

L-thyroxine efficacy after grapefruit juice ingestion. Grapefruit juice is known to inhibit intestinal OATP2B1 (Satoh
et al., 2005). The investigators found that grapefruit juice
slightly reduced the L-thyroxine area under the plasma
concentration-time curve by 9% within 0–6 hours, which was
concluded to be clinically insignificant. While this finding

Fig. 8. TRa-mediated transactivation of the SLCO2B1-1b or SLCO2B1-1e promoter. Arrangement of the respective region of the SLCO2B1 gene locus
depicting the different exons 1a to 1e. For the transcriptional start site variants SLCO2B1-1B and 1E, details on the localization of potential thyroid
hormone receptor response elements in the respective promoter region are shown (A). Cell-based reporter gene assays were performed in HeLa cells
transiently transfected with the SLCO2B1-1b (B), SLCO2B1-1e (C), or the Dio1 (D) promoter and treated with T3 (10 mM) or solvent control. Data are
shown as the mean luciferase activity fold of pGL3-basic (n = 3 independent replicates each in triplicate); *, ,0.05 Student’s t test.
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SLCO2B1-1b promoter
DR4-III†
DR4-II
ER6-II
ER6-I†
DR4-I
SLCO2B1-1e promoter
DR4-IV†
DR1-V
ER6-I
DR4-III
DR1-IV
DR1-III
DR1-II
DR4-II
DR4-1
DR1-I†*

Sequence
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after long-term treatment with L-thyroxine was found to
explain this clinical drug-drug interaction. Lastly, Siegmund
et al. (2002) reported induction of intestinal ABCB1 in
humans treated with L-thyroxine. However, this induction of
ABCB1 resulted only in minor, nonclinically relevant changes
in the pharmacokinetics of talinolol, an ABCB1 substrate
(Siegmund et al., 2002). It is interesting that talinolol is also a
substrate of the uptake transporters OATP2B1 and OATP1A2
(Shirasaka et al., 2010), despite that it is not anionic. It is
possible that TH-mediated upregulation of the intestinal
efflux mechanisms could be counteracted by the concomitant
upregulation of OATP2B1, leading to minimal pharmacokinetic consequences for talinolol.
In conclusion, we report that T3 and T4 are substrates of
OATP2B1, indicating a novel mechanism for regulation of TH
homeostasis by influencing hormone distribution and absorption during replacement therapy. In addition, we showed
upregulation of OATP2B1 by THs, which may be of relevance
for intestinal absorption of substrate drugs with narrow
therapeutic index.
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argues against the role of OATP2B1 in the oral absorption
of L-thyroxine, it is notable that inhibition of OATP2B1 by
grapefruit juice may be drug specific since the transporter
possesses two binding sites for substrates and inhibitors
(Shirasaka et al., 2012, 2014). Characterization of L-thyroxine
binding to the high- and low-affinity binding sites and modulation by grapefruit juice remains to be determined. Another
explanation for the lack of a significant pharmacokinetic
interaction in the aforementioned study may be that it was
conducted with healthy volunteers, while in the clinical case
report the patient had hypothyroidism. The possibility that
hypothyroidism may influence the magnitude of the juice/
L-thyroxine interaction is supported by our finding that
OATP2B1 expression is regulated by THs.
We showed upregulation of OATP2B1 mRNA and protein
expression in Caco-2 cells by THs, suggesting that TH status
influences the expression and activity of the intestinal uptake
transporter. A similar transcriptional regulation was observed when assessed in LS180 cells, an additional intestinal
cell model previously used to show induction of ABCB1 after
exposure to THs (Mitin et al., 2004). Interestingly, when
examined in Huh-7 and HepG2 cells, models for hepatocytes,
THs did not affect OATP2B1 expression, pointing to cell
model–specific regulation. Expression of TRb was observed
in all cell models used in our study, suggesting that differential expression of this receptor is not the reason underlying the
cell-specific effect. In contrast, quantification of TRa revealed
a lower amount of this nuclear receptor in hepatic cell models,
suggesting that this nuclear receptor may be involved in the
regulation of OATP2B1 expression observed in the intestinal
cells. Two N-terminal protein variants of OATP2B1 (variants
1B and 1E) have been described; these variants are assumed
to be transcriptionally regulated by different promoter regions
since their transcriptional start sites differ. In accordance are
findings showing that the liver-enriched SLCO2B1 1E, but not
the ubiquitously expressed SLCO2B1 1B transcriptional start
site variant, is regulated by the transcription factor HNF4a
(Knauer et al., 2013). However, with respect to regulation by
TRa we observed significant transactivation of both SLCO2B1
promoters. Considering that multiple potential binding sites
for TRs were predicted in the promoter sequences of SLCO2B11b and SLCO2B1-1e and that TRa is the predominant nuclear
receptor in intestine (Sirakov and Plateroti, 2011), differences in TRa expression levels may be the mechanism
underlying the observed differences in transcriptional regulation in hepatic (Huh-7 and HepG2) and intestinal (Caco2 and LS180) cells.
There is evidence that TH status modulates expression and
function of other drug transporters in the intestinal wall. For
example, the efflux transporter ABCB1 that limits intestinal
drug absorption is regulated by THs (Mitin et al., 2004).
Indeed, the required doses of the ABCB1 substrate digoxin
used to treat cardiac failure and to control heart rate differ
among patients suffering from hyper- or hypothyroidism
compared with patients with normal thyroid function. Specifically, higher and lower digoxin maintenance doses are needed
with hyperthyroidism and hypothyroidism, respectively (Burk
et al., 2010). It is notable that digoxin is not a substrate of
OATP2B1 (Taub et al., 2011). Another study by Jin et al.
(2005) showed that the trough plasma concentrations of the
ABCB1 substrate cyclosporin A were lower in patients taking
L-thyroxine. Increased expression of abcb1a/abcb1b in mice
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